References
- Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010 Sep;17(3-4):101-4. doi: 10.3109/13506129.2010.526812
- Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyhoid. 2020 Dec;27(4):217-222. doi: 10.1080/13506129.2020.1835263
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144
- Comenzo RL. How I treat amyloidosis. Blood. 2009 Oct 8;114(15):3147-57. doi: 10.1182/blood-2009-04-202879
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997 Sep 25;337(13):898-909. doi: 10.1056/NEJM199709253371306
- Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402
- Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020 Nov 10;10(11):118. doi: 10.1038/s41408-020-00385-0
- Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004 Oct 12;110(15):2168-74. doi: 10.1161/01.CIR.0000144310.04433.BE
- Hwa YL, Gertz MA, Kumar SK, et al. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5
- Abdallah N, Dispenzieri A, Muchtar E, et al. Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv. 2021 Feb 23;5(4):1029-1036. doi: 10.1182/bloodadvances.2020003782
- Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15;104(6):1881-7. doi: 10.1182/blood-2004-01-0390
- Palladini G, Paiva B, Wechalekar A, et al. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021 Feb 16;11(2):34. doi: 10.1038/s41408-021-00428-0
- Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724
- Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. doi: 10.1056/NEJM199704243361702
- Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010 Dec 9;116(24):5126-9. doi: 10.1182/blood-2010-06-290668
- Muchtar E, Magen H, Itchaki G, et al. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. Leuk Res. 2016 Feb;41:56-61. doi: 10.1016/j.leukres.2015.11.013
- Rodríguez-Lobato LG, Fernández de Larrea C, Cibeira MT, et al. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid. 2017 Dec;24(4):245-252. doi: 10.1080/13506129.2017.1390451
- Sachchithanantham S, Berlanga O, Alvi A, et al. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis. Br J Haematol. 2017 Nov;179(4):575-585. doi: 10.1111/bjh.14908
- Muchtar E, Dispenzieri A, Kumar SK, et al. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016 Sep;101(9):1102-9. doi: 10.3324/haematol.2016.147041
- Dittrich T, Bochtler T, Kimmich C, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475
- Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467
- Qiu Y, Zhang C, Shen K, et al. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels. Ann Hematol. 2018 Dec;97(12):2465-2470. doi: 10.1007/s00277-018-3460-0
- Sidana S, Tandon N, Dispenzieri A, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018 Mar;32(3):729-735. doi: 10.1038/leu.2017.286
- Kastritis E, Papassotiriou I, Terpos E, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016 Jul 21;128(3):405-9. doi: 10.1182/blood-2016-02-702696
- Pudusseri A, Sanchorawala V, Sloan JM, et al. Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis. Am J Hematol. 2019 Oct;94(10):1098-1103. doi: 10.1002/ajh.25576
- Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008 Mar;83(3):297-303. doi: 10.4065/83.3.297
- Yogo T, Okazuka K, Nashimoto J, et al. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis. Int J Hematol. 2019 Oct;110(4):431-437. doi: 10.1007/s12185-019-02692-0
- Kastritis E, Papassotiriou I, Merlini G, et al. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904
- Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999 Mar;84(3):218-21.
- Dinner S, Witteles W, Witteles R, et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol. 2013 May;161(3):367-72. doi: 10.1111/bjh.12269
- Tovar N, Rodríguez-Lobato LG, Cibeira MT, et al. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid. 2018 Jun;25(2):79-85. doi: 10.1080/13506129.2018.1443439
- Ozga M, Zhao Q, Benson D
Jr , et al. AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. Cancer Med. 2021 Feb; 10(3):965-73. doi: 10.1002/cam4.3683 - Kobayashi H, Abe Y, Miura D, et al. Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma. Jpn J Clin Oncol. 2019 Feb 1;49(2):195-198. doi: 10.1093/jjco/hyy202
- Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947
- Bochtler T, Hegenbart U, Kunz C, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361
- Sidana S, Tandon N, Brady PA, et al. Prognostic significance of Holter monitor findings in patients with light chain amyloidosis. Mayo Clin Proc. 2019 Mar;94(3):455-464. doi: 10.1016/j.mayocp.2018.08.039
- Nagano N, Yano T, Fujita Y, et al. Assessment of prognosis in immunoglobulin light chain amyloidosis patients with severe heart failure: a predictive value of right ventricular function. Heart Vessels. 2020 Apr;35(4):521-530. doi: 10.1007/s00380-019-01513-y
- Buss SJ, Emami M, Mereles, D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012 Sep 18;60(12):1067-76. doi: 10.1016/j.jacc.2012.04.043
- Pun SC, Landau HJ, Riedel ER, et al. Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation. J Am Soc Echocardiogr. 2018 Jan;31(1):64-70. doi: 10.1016/j.echo.2017.08.017
- Lei C, Zhu X, Hsi DH, et al. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. BMC Cardiovasc Disord. 2021 Jan 21;21(1):43. doi: 10.1186/s12872-021-01856-3
- Mohty D, Boulogne C, Magne J, et al. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2016 Sep;17(9):961-9. doi: 10.1093/ehjci/jew100
- Arenja N, Andre F, Riffel JH, et al. Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis. J Cardiovasc Magn Reson. 2019 Aug 22;21(1):53. doi: 10.1186/s12968-019-0564-1
- Wan K, Lin J, Guo X, et al. Prognostic value of right ventricular dysfunction in patients with AL amyloidosis: comparison of different techniques by cardiac magnetic resonance. J Magn Reson Imaging. 2020 Nov;52(5):1441-1448. doi: 10.1002/jmri.27200
- Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Sci Rep. 2019 Jun 12;9(1):8552. doi: 10.1038/s41598-019-44912-x
- Mohty D, Pradel S, Magne J, et al. Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Clin Res Cardiol. 2017 May;106(5):331-340. doi: 10.1007/s00392-016-1058-x
- Cho H, Kim S-J, Shim CY, et al. Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. Leuk Res. 2017 Sep;60:36-43. doi: 10.1016/j.leukres.2017.06.008
- Kim D, Lee GY, Choi J-O, Kim K, Kim SJ, Jeon E-S. Associations of electrocardiographic parameters with left ventricular longitudinal strain and prognosis in cardiac light chain amyloidosis. Sci Rep. 2019 May 23;9(1):7746. doi: 10.1038/s41598-019-44245-9
- Medvedovsky AT, Pollak A, Shuvy M, Gotsman I. Prognostic significance of the frontal QRS-T angle in patients with AL cardiac amyloidosis. J Electrocardiol. Mar-Apr 2020;59:122-125. doi: 10.1016/j.jelectrocard.2020.02.001
- Li H, Wang Y, Lan P, et al. Electrocardiographic parameters and prognosis of renal light chain amyloidosis. Clin Cardiol. 2020 Oct;43(10):1160-1166. doi: 10.1002/clc.23426
- Stamatelopoulos K, Georgiopoulos G, Athanasouli F, et al. Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis. Circ Res. 2019 Sep 27;125(8):744-758. doi: 10.1161/CIRCRESAHA.119.314862
- Binder C, Duca F, Binder T, et al. Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. Clin Res Cardiol. 2021 Apr;110(4):532-543. doi: 10.1007/s00392-020-01698-7
- Shen K-N, Miao H-L, Zhang C-L, et al. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. Leuk Lymphoma. 2021 Apr;62(4):874-882. doi: 10.1080/10428194.2020.1849675
- Vaxman I, Sidiqi MH, Al Saleh AS, et al. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplant. 2021 Apr;56(4):928-935. doi: 10.1038/s41409-020-01136-2
- Muchtar E, Dispenzieri A, Jevremovic D, et al. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709
DOI: https://doi.org/10.14797/mdcvj.1070 | Journal eISSN: 1947-6108
Language: English
Page range: 27 - 35
Submitted on: Dec 2, 2021
Accepted on: Feb 2, 2022
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2022 Kelty R. Baker, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.